{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-004566","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.552625+00:00","generated_at":"2026-05-28T03:59:49.162720+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Lexeo Therapeutics posts updated corporate presentation; no material new information in 8-K","bullets":["Updated corporate presentation posted on website January 13, 2025, for investor and analyst meetings.","Presentation includes forward-looking statements on gene therapy trial plans and data timing.","No financial results, leadership changes, or other material events disclosed in this filing.","Risk factors from prior SEC filings are incorporated by reference."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-004566","json":"https://secwatch.observer/filing/0000950170-25-004566.json","markdown":"https://secwatch.observer/filing/0000950170-25-004566.md","text":"https://secwatch.observer/filing/0000950170-25-004566.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017025004566/0000950170-25-004566-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017025004566/lxeo-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:59:49.162720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}